<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pseudomonas aeruginosa skin and soft tissue infections
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pseudomonas aeruginosa skin and soft tissue infections
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pseudomonas aeruginosa skin and soft tissue infections
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Souha S Kanj, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel J Sexton, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sandra Nelson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keri K Hall, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Pseudomonas aeruginosa
         </em>
         is one of the most commonly considered gram-negative aerobic bacilli in the differential diagnosis of gram-negative infections. Consideration of this organism is important because it causes severe and often fatal hospital-acquired infections, especially in immunocompromised hosts. Selection of antibiotic treatment for
         <em>
          P. aeruginosa
         </em>
         is complicated because it is often antibiotic resistant.
        </p>
        <p>
         The clinical manifestations, diagnosis, and treatment of
         <em>
          P. aeruginosa
         </em>
         skin, soft tissue, and bone infections will be reviewed here.
        </p>
        <p>
         The general principles of antimicrobial treatment of infections caused by
         <em>
          P. aeruginosa
         </em>
         , including antibiotic options and decisions on combination therapy, are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">
          "Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"
         </a>
         .)
        </p>
        <p>
         The clinical manifestations and management of other
         <em>
          P. aeruginosa
         </em>
         infections and the epidemiology and pathogenesis of infection with this organism are also discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3142.html" rel="external">
          "Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2136.html" rel="external">
          "Pseudomonas aeruginosa bacteremia and endocarditis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3133.html" rel="external">
          "Pseudomonas aeruginosa pneumonia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3148.html" rel="external">
          "Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1210513851">
         <span class="h1">
          CLINICAL SYNDROMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. aeruginosa
         </em>
         can cause various specific clinical skin, soft tissue, and bone infections. Certain syndromes are classically or most commonly associated with
         <em>
          P. aeruginosa
         </em>
         , specifically. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ecthyma gangrenosum
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Burn wound infections
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Folliculitis associated with hot tub exposures
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Foot infection following nail puncture injury
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Green nail syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perichondritis following ear piercing or acupuncture
        </p>
        <p>
        </p>
        <p>
         These are discussed in further detail below.
        </p>
        <p>
         Additionally,
         <em>
          P. aeruginosa
         </em>
         can be involved in other general skin and soft tissue infections, such as cellulitis (particularly in neutropenic patients), postoperative infections, infections following trauma (particularly after injury in aquatic environments), and infections of chronic decubitus ulcers.
         <em>
          P. aeruginosa
         </em>
         osteomyelitis can result from direct invasion or hematogenous spread, especially in injection drug users. Inflammatory subcutaneous nodules (ie, panniculitis) due to
         <em>
          P. aeruginosa
         </em>
         in the absence of bacteremia or classic immunosuppression have been rarely reported [
         <a href="#rid1">
          1
         </a>
         ]. Skull base osteomyelitis associated with malignant otitis externa is most commonly caused by
         <em>
          P. aeruginosa
         </em>
         and is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3413.html" rel="external">
          "Malignant (necrotizing) external otitis"
         </a>
         .)
        </p>
        <p>
         As with other infections,
         <em>
          P. aeruginosa
         </em>
         soft tissue infections are often associated with worse outcomes than other pathogens. As an example, in a prospective study of 132 patients who received skin grafts for soft-tissue defects,
         <em>
          P. aeruginosa
         </em>
         was the most common etiologic microorganism in skin-graft loss due to infection (58 percent) [
         <a href="#rid2">
          2
         </a>
         ]. Infections due to
         <em>
          P. aeruginosa
         </em>
         were more fulminant and were 4.2 times more likely to require reoperation that those caused by other organisms.
        </p>
        <p class="headingAnchor" id="H1210515359">
         <span class="h1">
          MANAGEMENT PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, treatment of
         <em>
          P. aeruginosa
         </em>
         skin, soft tissue, and bone infections should include aggressive surgical debridement of any necrotic tissue and infected eschars, in addition to antibiotic therapy. Antibiotic options include beta-lactams, carbapenems, or fluoroquinolones that have antipseudomonal activity (
         <a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">
          table 1
         </a>
         ). In general, aminoglycosides should not be used as a single agent for infection at these sites.
        </p>
        <p>
         Advanced beta-lactam beta-lactamase inhibitor combinations (such as
         <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">
          ceftolozane-tazobactam
         </a>
         ,
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         ) may also have a role in treating skin, soft tissue, and bone infections caused by multidrug-resistant and extensively drug-resistant
         <em>
          P. aeruginosa
         </em>
         infections if other agents are not feasible (eg, because of drug allergy) [
         <a href="#rid3">
          3-5
         </a>
         ]. A recent study assessing the susceptibility of
         <em>
          P. aeruginosa
         </em>
         strains causing SSTIs that were isolated from 47 centers from various countries reported that 98.6 percent of strains were susceptible to ceftolozane-tazobactam, 98.3 percent were susceptible to ceftazidime-avibactam, and 98.3 percent were susceptible to imipenem-relebactam [
         <a href="#rid6">
          6
         </a>
         ]. In fact, a recent systematic review showed that SSTIs caused by difficult-to-treat
         <em>
          P. aeruginosa
         </em>
         are the most common indication for off-label use of ceftolozane-tazobactam (37.7 percent) with a clinical success rate of 79.6 percent [
         <a href="#rid7">
          7
         </a>
         ]. Additionally, most real-world experiences with ceftolozane-tazobactam have shown good clinical outcomes in the subset of patients with SSTIs due to
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid8">
          8,9
         </a>
         ]. Hence, novel antipseudomonal agents may soon be recommended as first-line therapy for difficult-to-treat
         <em>
          P. aeruginosa
         </em>
         SSTIs [
         <a href="#rid10">
          10
         </a>
         ]. Although the fluoroquinolone
         <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">
          delafloxacin
         </a>
         has theoretical utility for polymicrobial soft tissue infections when coverage against both
         <em>
          P.
         </em>
         <em>
          aeruginosa
         </em>
         and methicillin-resistant
         <em>
          Staphylococcus aureus
         </em>
         (MRSA) is desired, we generally use other better established regimens pending further data on its use.
        </p>
        <p>
         Specific antipseudomonal agents and doses are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">
          "Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Antibiotics with antipseudomonal activity'
         </a>
         .)
        </p>
        <p>
         The usual duration of antimicrobial therapy for skin and soft tissue infection is 10 to 14 days; however, shorter courses may be acceptable if the clinical signs and symptoms of infection have resolved. Occasional patients will continue to have local signs of infection at the end of two weeks of treatment. We generally continue oral antibiotic therapy (if the isolate is susceptible) in these patients until resolution of all erythema has occurred. Routine bedside re-evaluation is essential and antimicrobial therapy should be reconsidered when other noninfectious causes are more likely and the
         <em>
          Pseudomonas
         </em>
         is felt to be a colonizer [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         The usual duration of antimicrobial therapy for osteomyelitis is six weeks following surgical debridement. If the isolate is fluoroquinolone susceptible, therapy with oral
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         (750 mg twice daily) can be used.
        </p>
        <p>
         Specifics on the management of ecthyma gangrenosum, burn infections, folliculitis, infections following nail puncture, and green nail syndrome are discussed below.
        </p>
        <p class="headingAnchor" id="H1133434152">
         <span class="h1">
          ECTHYMA GANGRENOSUM
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. aeruginosa
         </em>
         has been classically associated with a characteristic skin lesion called ecthyma gangrenosum (
         <a class="graphic graphic_picture graphicRef80582" href="/z/d/graphic/80582.html" rel="external">
          picture 1
         </a>
         ), which is most frequently described in the setting of bacteremia in immunocompromised patients. It results from perivascular bacterial invasion of the media and adventitia of arteries and veins with secondary ischemic necrosis. Ecthyma refers to an ulcerative lesion that extends through the epidermis and deep into the dermis and appears as a "punched-out" ulcer covered in crust surrounded by raised violaceous margins. Although ecthyma gangrenosum is not pathognomonic of
         <em>
          P. aeruginosa
         </em>
         infection, the presence of these lesions should immediately raise the high probability that
         <em>
          P. aeruginosa
         </em>
         is the causative organism. This is particularly important for critically ill patients who present with severe sepsis and require prompt antipseudomonal empiric antimicrobial therapy [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20689149">
         <span class="h2">
          Epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ecthyma gangrenosum is classically associated with
         <em>
          P. aeruginosa
         </em>
         sepsis and bacteremia in immunocompromised patients, including those with neutropenia or congenital immunodeficiencies (eg, Bruton agammaglobulinemia [
         <a href="#rid14">
          14,15
         </a>
         ]) and those on immune modulating agents. It has been observed in approximately 1.3 to 3 percent of
         <em>
          P. aeruginosa
         </em>
         bacteremia cases [
         <a href="#rid16">
          16
         </a>
         ]. In some cases, ecthyma has been described in patients who were subsequently discovered to have an immune deficit [
         <a href="#rid17">
          17
         </a>
         ]. Furthermore, it has also been reported in healthy, immunocompetent patients without bacteremia or systemic infection. In such patients, ecthyma gangrenosum can present as localized skin lesions [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Lesions may occur after breakdown of mechanical defense barriers and local infection [
         <a href="#rid18">
          18
         </a>
         ]. Diabetes and malnutrition have been identified as predisposing factors in patients without classic immunocompromise [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1210515389">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ecthyma gangrenosum results from perivascular bacterial invasion of the media and adventitia of arteries and veins with secondary ischemic necrosis.
        </p>
        <p>
         <em>
          Pseudomonas
         </em>
         produces several toxins that mediate the process of tissue degradation. Exotoxin A inhibits protein synthesis and elastase degrades elastin, thereby destroying the blood vessel wall support. Phospholipase C breaks down phospholipids in cell membranes and pyocyanin produces reactive oxygen species toxic to cells [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1210514982">
         <span class="h2">
          Clinical findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         The lesions of ecthyma gangrenosum (
         <a class="graphic graphic_picture graphicRef80582" href="/z/d/graphic/80582.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef114332" href="/z/d/graphic/114332.html" rel="external">
          picture 2
         </a>
         ) commonly begin as painless red macules which rapidly evolve into areas of induration that develop into pustules and/or bullae. Ultimately, these become gangrenous ulcers. Ecthyma lesions typically progress rapidly (within 12 to 18 hours). The lesions may involve the skin or mucous membranes.
        </p>
        <p>
         Although ecthyma gangrenosum can occur at any anatomic location, the anogenital and axillary areas are most commonly involved [
         <a href="#rid16">
          16
         </a>
         ]. The gluteal and perineal areas are involved in 57 percent of cases, extremities in 30 percent, the trunk in 6 percent, and the face in 6 percent. Periorbital lesions are very rare but have been described.
        </p>
        <p>
         Lesions may be single or multiple; in the latter case, they may be in different stages of development at any given point in time.
        </p>
        <p>
         Biopsy of ecthyma gangrenosum lesions typically shows hemorrhagic necrosis, gram-negative bacilli, and damage to the media of arterial blood vessels [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Most patients have fever and may be systemically ill; however, ecthyma gangrenosum can occur in patients in the absence of fever or other constitutional signs.
        </p>
        <p class="headingAnchor" id="H1210515007">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ecthyma gangrenosum is not pathognomonic of
         <em>
          P. aeruginosa
         </em>
         infection. Identical lesions have been seen with systemic infection due to an array of common and uncommon bacterial, viral, and fungal pathogens [
         <a href="#rid20">
          20
         </a>
         ]. Among bacterial pathogens,
         <em>
          Pseudomonas stutzeri
         </em>
         ,
         <em>
          Aeromonas
         </em>
         spp,
         <em>
          Stenotrophomonas
         </em>
         spp,
         <em>
          Citrobacter
         </em>
         spp, methicillin-resistant
         <em>
          S. aureus
         </em>
         , and atypical mycobacteria have been described to cause ecthyma gangrenosum. Among fungal infections,
         <em>
          Fusarium
         </em>
         spp have been classically associated with ecthyma gangrenosum, and a few reports have described ecthyma gangrenosum-like lesions in immunocompromised patients with disseminated candidiasis [
         <a href="#rid21">
          21,22
         </a>
         ]. It should be noted that when other pathogens are isolated from ecthyma gangrenosum lesions in addition to
         <em>
          P. aeruginosa
         </em>
         , the possibility of contamination should be considered.
        </p>
        <p>
         In light of the broad microbial differential diagnosis, efforts to identify the causative pathogen in every patient are warranted. These are discussed below. (See
         <a class="local">
          'Diagnosis and evaluation'
         </a>
         below.)
        </p>
        <p>
         Pyoderma gangrenosum may rarely be confused with ecthyma gangrenosum when it is evolving from a pustule or vesicle into a typical cutaneous ulcer. However, the lesions of pyoderma gangrenosum are not due to an infection, they are usually tender, and patients are typically not systemically sick. (See
         <a class="medical medical_review" href="/z/d/html/13782.html" rel="external">
          "Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1210515013">
         <span class="h2">
          Diagnosis and evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of ecthyma gangrenosum is generally made based on the characteristic clinical appearance of the lesions in the appropriate clinical setting. The presence of these lesions should immediately raise the possibility of bacteremia, particularly with
         <em>
          P. aeruginosa
         </em>
         , and should thus prompt the collection of blood cultures if not already performed. However, the absence of growth on blood cultures does not rule out the diagnosis of ecthyma.
        </p>
        <p>
         A specific microbial diagnosis is important given that many different organisms can cause ecthyma gangrenosum, which is another reason for collecting blood cultures. Culture of exudates from an aspirate or swab of lesions is easy to perform and may identify a causative pathogen. If both blood cultures and cultures from skin exudates are negative, a biopsy of the lesion for pathology and bacterial, fungal, and mycobacterial cultures may be useful to exclude other etiologies. In fact, an early skin biopsy may be beneficial in immunocompromised hosts to rule out nonbacterial causative organisms like fungi that can be visualized on direct observation of specimens and require prompt antifungal treatment [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1210515395">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the typical involvement of
         <em>
          P. aeruginosa
         </em>
         , empiric antimicrobial therapy of a lesion suspicious for ecthyma gangrenosum should include an agent with antipseudomonal activity (
         <a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">
          table 1
         </a>
         ). The choice of agent should take into account the local epidemiology and resistance rates. In a recent retrospective study of pediatric patients with hematologic and solid organ malignancy and ecthyma gangrenosum, over 30 percent of the isolated strains were multidrug-resistant
         <em>
          P. aeruginosa
         </em>
         with one out of three isolates being resistant to
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         , highlighting the burden of antimicrobial resistance in this patient population [
         <a href="#rid24">
          24
         </a>
         ]. In certain high-risk patients (eg, neutropenic or otherwise immunocompromised) and those with severe infections (eg, sepsis or septic shock), we favor the use of a combination antimicrobial regimen for initial empiric therapy. The rationale for the use of combination therapy is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">
          "Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Role of combination antimicrobial therapy'
         </a>
         .)
        </p>
        <p>
         Once the causative organism and its susceptibility pattern are identified, directed therapy with a single active agent can be tailored to these results. Specific antimicrobial options for
         <em>
          P. aeruginosa
         </em>
         infections are discussed elsewhere (
         <a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Although not generally warranted for infections with limited involvement, surgical debridement to achieve source control and even skin grafting may be necessary in patients with severe or extensive skin [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Nonantibiotic alternative therapies have been considered to target biofilm formation, which plays an important role in
         <em>
          P. aeruginosa
         </em>
         proliferation and resistance to treatment in ecthyma gangrenosum [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          BURN INFECTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. aeruginosa
         </em>
         skin infection complicating burn injuries is a severe infection often associated with antibiotic resistance that warrants combination empiric therapy. These infections often have a poor outcome despite the use of appropriate antibiotic therapy [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. aeruginosa
         </em>
         is one of the most commonly isolated organisms from burn patients, accounting for 57 percent of positive swab and tissue culture results in one study [
         <a href="#rid29">
          29
         </a>
         ]. According to a systematic review and meta-analysis,
         <em>
          P. aeruginosa
         </em>
         is the most common causative organism among Gram-negative-associated burn wound infections and is an independent predictor of mortality [
         <a href="#rid30">
          30
         </a>
         ]. Burn wound infection with
         <em>
          P. aeruginosa
         </em>
         occurs most commonly after the first week of hospitalization, highlighting the importance of infection prevention and control practices to reduce the risk of infection [
         <a href="#rid31">
          31
         </a>
         ]. Rates of bacteremia due to
         <em>
          P. aeruginosa
         </em>
         vary by center. In one study of 5882 burn patients admitted to a burn center over a 25 year period,
         <em>
          P. aeruginosa
         </em>
         bacteremia occurred in 9 percent of cases [
         <a href="#rid27">
          27
         </a>
         ]. The mortality rates in patients with and without bacteremia were 77 and 49 percent, respectively. In another study, bacteremia occurred in 7 percent of 1415 burn patients; 15 percent of these bacteremic patients were infected with
         <em>
          P. aeruginosa
         </em>
         (1 percent overall) [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         Among children, factors associated with an increased risk of infection with
         <em>
          P. aeruginosa
         </em>
         include flame and inhalation burns, full thickness burns, and total body surface area involvement greater than 30 percent [
         <a href="#rid32">
          32
         </a>
         ]. A retrospective analysis of
         <em>
          P. aeruginosa
         </em>
         bacteremia in children found that 7 percent of cases occurred in burn patients; mortality among burn patients was greater than oncology patients and other patients (40 versus 19 and 11 percent, respectively) [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Pathogenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with extensive burns are considered to be immunosuppressed on the basis of altered neutrophil activity, T lymphocyte dysfunction, and imbalance in the production of cytokines [
         <a href="#rid34">
          34-36
         </a>
         ]. Colonization of the burn eschar site with
         <em>
          P. aeruginosa
         </em>
         (up to 10
         <sup>
          5
         </sup>
         of bacteria per gram of tissue) is common. Burns destroy the physical barrier to tissue invasion; this in turn allows bacteria on the surface of the skin to invade into the dermis and enter the lymphatics along fibrous septae. After such invasion, organisms can proliferate in necrotic tissue and invade blood vessels, producing a secondary bacteremia.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Physical findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examination of the skin in patients with burn injuries complicated by
         <em>
          P. aeruginosa
         </em>
         infection typically reveals discoloration of the burn eschar, bleeding in the subcutaneous tissue, and degeneration of the granulation tissue. Healthy adjacent tissue may rapidly develop edema, hemorrhage, and necrosis, with new nodular lesions and eschars forming by centrifugal spread. Systemic signs and symptoms identical to those seen with other systemic bacterial infections are usually present.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of
         <em>
          P. aeruginosa
         </em>
         infection in burn patients can be made through growth of the organism on quantitative cultures from a biopsy obtained from the burn skin as well as adjacent unburned tissue [
         <a href="#rid37">
          37
         </a>
         ]. A colony count of 10
         <sup>
          5
         </sup>
         organisms per gram of tissue in the setting of consistent clinical findings is indicative of a burn wound infection, as opposed to simple colonization. The distinction between the varying levels of bacterial involvement in burn wound infections is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14985.html" rel="external">
          "Burn wound infection and sepsis", section on 'Differential diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14985.html" rel="external">
          "Burn wound infection and sepsis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Molecular testing with polymerase chain reaction (PCR) could be a useful tool to detect
         <em>
          P. aeruginosa
         </em>
         in burn wounds, but it is not widely available beyond research studies [
         <a href="#rid38">
          38
         </a>
         ]. It provides rapid results and can distinguish
         <em>
          P. aeruginosa
         </em>
         from other
         <em>
          Pseudomonas
         </em>
         species and other gram-negative bacilli that might resemble
         <em>
          P. aeruginosa
         </em>
         through conventional diagnostic methods. Novel diagnostic tools, such as peptide nucleic acid fluorescent in situ hybridization (PNA-FISH) and matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (MS), may accelerate bacterial identification and susceptibility testing and improve the time to appropriate antimicrobial treatment [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1210514707">
         <span class="h2">
          Antimicrobial resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         A high rate of antibiotic resistance has been observed in burn patients with
         <em>
          P. aeruginosa
         </em>
         infections, and this affects decisions about empiric therapy. As an example, in a study of 70
         <em>
          P. aeruginosa
         </em>
         isolates from patients in a burn center in Iran, 89 percent were resistant to ticarcillin-clavulanate, 76 percent to
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         , and 20 percent to
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         [
         <a href="#rid40">
          40
         </a>
         ]. In another study from Rio de Janeiro, 71 percent of the 35 isolates of
         <em>
          P. aeruginosa
         </em>
         recovered from burn patients or burn unit environment were multidrug-resistant [
         <a href="#rid41">
          41
         </a>
         ]. Another study from a burn center in Sweden reported that 26 percent of
         <em>
          P. aeruginosa
         </em>
         isolates from 1994 to 2012 were carbapenem-resistant [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         Certain features may be associated with a greater likelihood of infection with resistant organisms. Risk factors for acquisition of imipenem-resistant
         <em>
          P. aeruginosa
         </em>
         were identified in a multivariate analysis of 133 patients (93 with imipenem-resistant and 40 with imipenem-sensitive
         <em>
          P. aeruginosa
         </em>
         ) hospitalized in a burn unit in Turkey between July 2003 and November 2004 [
         <a href="#rid43">
          43
         </a>
         ]. Independent risk factors included:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior carbapenem use (odds ratio [OR], 7.4)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior broad-spectrum antibiotic use (OR, 6.5)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Length of hospitalization (OR, 3.6)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of imipenem-resistant
         <em>
          P. aeruginosa
         </em>
         in the unit (OR, 2.6)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Previous presence of imipenem-sensitive
         <em>
          P. aeruginosa
         </em>
         in the patient (OR, 1.7)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of
         <em>
          P. aeruginosa
         </em>
         burn wound infections involves aggressive surgical debridement of necrotic tissue and infected eschar, as well as systemic antimicrobial therapy.
        </p>
        <p>
         For empiric therapy prior to the availability of susceptibility testing results in burn patients with serious
         <em>
          P. aeruginosa
         </em>
         wound infections, we suggest a combination of two antibiotics because of the high load of organisms and the likelihood of infection with or development of resistant organisms. Possible regimens include
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         ,
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         , or an antipseudomonal carbapenem each in combination with an aminoglycoside (
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         , or
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         ) (
         <a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">
          table 1
         </a>
         ). The rationale for combination therapy and discussion of aminoglycoside dosing are found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">
          "Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Role of combination antimicrobial therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/475.html" rel="external">
          "Dosing and administration of parenteral aminoglycosides"
         </a>
         .)
        </p>
        <p>
         Once susceptibility testing results are available, directed therapy with a single agent guided by these results is preferable, if possible. Specific antimicrobial options for
         <em>
          P. aeruginosa
         </em>
         infections are discussed elsewhere (
         <a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">
          "Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Antibiotics with antipseudomonal activity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">
          "Principles of antimicrobial therapy of Pseudomonas aeruginosa infections", section on 'Antibiotic selection'
         </a>
         .)
        </p>
        <p>
         When a skin and soft tissue infection with a carbapenem-resistant
         <em>
          P. aeruginosa
         </em>
         (CRPA) is suspected or documented,
         <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">
          ceftolozane-tazobactam
         </a>
         ,
         <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">
          ceftazidime-avibactam
         </a>
         , imipenem-relebactam, and
         <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">
          cefiderocol
         </a>
         can be used [
         <a href="#rid44">
          44
         </a>
         ]. The novel fluoroquinolones finafloxacin and
         <a class="drug drug_general" data-topicid="113710" href="/z/d/drug information/113710.html" rel="external">
          delafloxacin
         </a>
         also appear promising for the treatment of CRPA [
         <a href="#rid45">
          45
         </a>
         ]
        </p>
        <p>
         Treatment of multidrug-resistant pathogens, including
         <em>
          P. aeruginosa,
         </em>
         with bacteriophages is being evaluated in patients with burns and device-related infections. In one randomized study of 27 patients, a cocktail of topical bacteriophages was used to treat burn wounds infected with
         <em>
          P. aeruginosa
         </em>
         ; half of those who received the bacteriophage cocktail had a reduced quantity of bacteria in the wound, although this was a lower proportion than those who received standard of care [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Management of the burn wound itself is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14990.html" rel="external">
          "Overview of surgical procedures used in the management of burn injuries"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14985.html" rel="external">
          "Burn wound infection and sepsis", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         The mortality of
         <em>
          P. aeruginosa
         </em>
         burn wound infections and associated sepsis can be very high [
         <a href="#rid27">
          27,28
         </a>
         ]. However, early diagnosis and prompt treatment of infections in the setting of burns, even those caused by
         <em>
          P. aeruginosa
         </em>
         , can be associated with a considerably lower mortality rate, nine percent in one series [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H299518596">
         <span class="h2">
          Prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the higher rate of antimicrobial resistance and the associated difficulty in treating these infections, prevention of
         <em>
          P. aeruginosa
         </em>
         infections is an especially important strategy to reduce the burden of disease. Measures to decrease the incidence of infection by attempting to reduce the colonizing bacterial population have been used. These include cleaning, debridement, and dressing, as well as application of topical antimicrobials. The local and surgical management of burn wounds for prevention of infection is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/13509.html" rel="external">
          "Topical agents and dressings for local burn wound care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14985.html" rel="external">
          "Burn wound infection and sepsis", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         Protection against subsequent
         <em>
          P. aeruginosa
         </em>
         infections through vaccination is under evaluation [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          HOT TUB-ASSOCIATED ERUPTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         "Hot tub folliculitis and hot foot syndrome" are benign, self-limited skin lesions caused by
         <em>
          P. aeruginosa
         </em>
         that can occur following exposure to contaminated water.
        </p>
        <p>
         <em>
          P. aeruginosa
         </em>
         folliculitis is typically associated with the use of spa pools, whirlpools, or exposure to inadequately chlorinated swimming pools and hot tubs [
         <a href="#rid49">
          49,50
         </a>
         ]. Two outbreaks of
         <em>
          P. aeruginosa
         </em>
         folliculitis from hotel swimming pool and hot tub exposures were described in Colorado and Maine in 1999 and 2000; both facilities used offsite maintenance crews and free levels of chlorine were found to be low [
         <a href="#rid50">
          50
         </a>
         ]. Additional risk factors that may increase the risk of hot-tub folliculitis include female sex, alterations of skin flora, length of hot-tub exposure, and underlying skin trauma [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         <em>
          P. aeruginosa
         </em>
         folliculitis typically develops 8 to 48 hours after exposure to contaminated water. The eruption in
         <em>
          P. aeruginosa
         </em>
         folliculitis consists of tender and pruritic papules, papulopustules, or nodules (
         <a class="graphic graphic_picture graphicRef65119" href="/z/d/graphic/65119.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid52">
          52-54
         </a>
         ]. Most patients have malaise and some have low grade fever (42 and 22 percent, respectively in the Colorado and Maine outbreaks noted above) [
         <a href="#rid50">
          50
         </a>
         ]. Urticarial lesions on the trunk, extremities, hands, and feet have also been reported [
         <a href="#rid52">
          52-55
         </a>
         ]. In one outbreak of folliculitis in Alaska among bathers in a contaminated hot tub, five of nine affected bathers had inflammation of Montgomery's follicles of the breast [
         <a href="#rid56">
          56
         </a>
         ]. Longer periods of bathing and bathing later in the day were associated with an increased risk of disease.
        </p>
        <p>
         A variation on this entity has been reported, consisting of tender erythematous nodules on the soles of the feet and labelled "pseudomonas hot foot syndrome" [
         <a href="#rid55">
          55,57,58
         </a>
         ]. A group of 40 children developed these lesions within 40 hours of wading in a pool with a rough floor and were unable to bear weight on the affected areas; culture of the wading pool water grew abundant
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid57">
          57
         </a>
         ]. All patients recovered without specific antibiotic therapy. It is thought that hot hand-foot syndrome is more common in children due to their thinner epidermis of the palms and soles [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         <em>
          P. aeruginosa
         </em>
         folliculitis and hot foot syndrome are self-limiting conditions that improve with removal of the exposure and symptomatic care. An oral fluoroquinolone (eg,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ) may be warranted for lesions that are persistent or cause significant discomfort. (See
         <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">
          "Infectious folliculitis", section on 'Pseudomonal folliculitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          INFECTION FOLLOWING NAIL PUNCTURE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. aeruginosa
         </em>
         osteochondritis, osteomyelitis, and septic arthritis following nail puncture wound to the foot is a well-described complication. This syndrome occurs predominantly in children with a history of wearing tennis shoes, [
         <a href="#rid60">
          60
         </a>
         ] but it also occurs in adults as well [
         <a href="#rid61">
          61
         </a>
         ]. The association with tennis shoes is possibly due to the moist inner sole of the shoe which would provide a suitable environment for growth of this organism [
         <a href="#rid62">
          62
         </a>
         ]. In one study,
         <em>
          P. aeruginosa
         </em>
         was isolated from the sneakers of seven of eight children with documented
         <em>
          P. aeruginosa
         </em>
         osteomyelitis following a plantar puncture wound and from 4 of 33 pairs of randomly selected worn and discarded sneakers, but not from unworn shoes; the organism was most frequently isolated from the inner foam layer of the sneaker sole. Evaluation, management, and prevention of infections following puncture wound injury, including pseudomonal plantar puncture wound infections, are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7661.html" rel="external">
          "Infectious complications of puncture wounds", section on 'Evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7661.html" rel="external">
          "Infectious complications of puncture wounds", section on 'Management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7661.html" rel="external">
          "Infectious complications of puncture wounds", section on 'Prevention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H377244765">
         <span class="h1">
          TOE WEB INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gram-negative interweb foot impetigo is a relatively common disorder and is often bilateral [
         <a href="#rid63">
          63
         </a>
         ]. Secondary cellulitis may occur.
        </p>
        <p>
         The infection is commonly associated with the use of closed-toe or tight-fitting shoes and in individuals in whom strong physical exertion plays an important role in athletic, occupational, or recreational activities. Other predisposing factors include interdigital tinea pedis, eczema, hyperhidrosis, diabetes mellitus, and self-medication with topical antifungals, antibiotics, and glucocorticoids [
         <a href="#rid63">
          63-68
         </a>
         ].
        </p>
        <p>
         Gram-negative mixed bacterial infection, including with
         <em>
          Pseudomonas
         </em>
         species, may represent a mild secondary infection of tinea pedis. Among patients with mixed gram-negative interweb foot infection,
         <em>
          P. aeruginosa
         </em>
         appears to be the most commonly isolated pathogen [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         No pathognomonic clinical presentation exists to differentiate gram-negative interweb foot infection from gram-positive or fungal infections. The condition initially presents as interdigital erythema with malodorous exudate, pain, and itching [
         <a href="#rid64">
          64
         </a>
         ] but can progress to advanced stages of gram-negative infection with sepsis if left untreated [
         <a href="#rid69">
          69
         </a>
         ]. For cases that are refractory to appropriate antibiotic therapy, the possibility of other processes, including eczematous dermatitis and malignancy, should be considered [
         <a href="#rid67">
          67,70,71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          GREEN NAIL SYNDROME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with chronic onycholytic toenails who have prolonged immersion exposure to fresh water may develop a characteristic green discoloration called the green nail syndrome [
         <a href="#rid54">
          54,72,73
         </a>
         ] (
         <a class="graphic graphic_picture graphicRef91405" href="/z/d/graphic/91405.html" rel="external">
          picture 4
         </a>
         and
         <a class="graphic graphic_picture graphicRef91406" href="/z/d/graphic/91406.html" rel="external">
          picture 5
         </a>
         and
         <a class="graphic graphic_picture graphicRef91407" href="/z/d/graphic/91407.html" rel="external">
          picture 6
         </a>
         ). This is almost always a complication of onycholysis or chronic paronychia and is usually restricted to one or two nails. In addition to the fungi associated with the onycholysis,
         <em>
          P. aeruginosa
         </em>
         is generally isolated from the nail. The green color is due to accumulation of debris below the nail and the pigment pyocyanin adhering to the undersurface of the nail plate. Although clinical and dermoscopic findings are enough to diagnose green nail syndrome, some patients may require gram stain, culture, histopathology, or more advanced diagnostics to confirm the diagnosis [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         Topical therapy is typically the first line treatment for this condition [
         <a href="#rid74">
          74-76
         </a>
         ]. Many patients respond to two weeks of topical fluoroquinolones and antiseptic soaks. Such antiseptic measures include applying acetic acid or
         <a class="drug drug_general" data-topicid="9958" href="/z/d/drug information/9958.html" rel="external">
          sulfacetamide
         </a>
         in 50 to 70 percent ethyl alcohol, 4 percent thymol in chloroform, or Clorox diluted in 1:4 two to three times a day to the space to suppress the growth of
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         In addition, the patient should be advised to avoid excessive immersion in hot water, even when wearing protective gloves. After washing, the nails should be dried thoroughly. In some cases, the use of a hair dryer is recommended to keep the nail plate-nail bed space as dry as possible. Thorough trimming should be repeated at intervals of four weeks until the normal nail regrows. Treatment of any underlying nail disease (eg, fungal infection, psoriasis) is indicated. (See
         <a class="medical medical_review" href="/z/d/html/4034.html" rel="external">
          "Onychomycosis: Epidemiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Systemic antibiotics may be warranted in patients who do not respond to topical treatment. Because the appearance is relatively characteristic and there can be difficulty in obtaining adequate samples for culture, we start empiric oral antimicrobial therapy in such patients. Oral
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         (500 to 750 mg PO BID) for a period of four weeks has been found to be effective [
         <a href="#rid78">
          78
         </a>
         ]. If there is no improvement, then nail removal with cultures and sensitivity testing would be a reasonable next step.
        </p>
        <p class="headingAnchor" id="H1031531184">
         <span class="h1">
          PERICHONDRITIS OF THE EAR
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          P. aeruginosa
         </em>
         perichondritis of the helix or tragus of the ear can occur after trauma, surgery, or burns, and a number of cases have been reported following piercing of the upper ear cartilage [
         <a href="#rid79">
          79
         </a>
         ].
         <em>
          P. aeruginosa
         </em>
         is more often isolated in suppurative perichondritis rather than nonabscess perichondritis [
         <a href="#rid80">
          80
         </a>
         ]. This is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3148.html" rel="external">
          "Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system", section on 'Perichondritis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H185138331">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/17202.html" rel="external">
          "Patient education: Bacterial folliculitis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H299518318">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical spectrum
         </strong>
         – Certain clinical syndromes are classically associated with
         <em>
          P. aeruginosa
         </em>
         . These include ecthyma gangrenosum, burn wound infections, infection following nail puncture, eruptions associated with hot tub exposures, green nail syndrome, and perichondritis of the ear. Additionally,
         <em>
          P. aeruginosa
         </em>
         can be involved in other more typical skin and soft tissue infections (eg, cellulitis), especially those in immunocompromised patients or following instrumentation or water exposure. (See
         <a class="local">
          'Clinical syndromes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Principles of management
         </strong>
         – In general, treatment of
         <em>
          P. aeruginosa
         </em>
         skin, soft tissue, and bone infections should include aggressive surgical debridement of any necrotic tissue and infected eschars, in addition to antibiotic therapy. Antibiotic options include beta-lactams, carbapenems, or fluoroquinolones that have antipseudomonal activity (
         <a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">
          table 1
         </a>
         ). Aminoglycosides should not be used as a single agent for infection at these sites. (See
         <a class="local">
          'Management principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ecthyma gangrenosum
         </strong>
         – Ecthyma gangrenosum is most commonly associated with bacteremia in immunocompromised hosts. The lesions begin as painless red macules which rapidly evolve into areas of induration that develop into pustules and/or bullae then ultimately become gangrenous ulcers (
         <a class="graphic graphic_picture graphicRef80582" href="/z/d/graphic/80582.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef114332" href="/z/d/graphic/114332.html" rel="external">
          picture 2
         </a>
         ). (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Clinical findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The diagnosis of ecthyma gangrenosum is generally made based on the clinical appearance of characteristic lesions. Cultures of blood and lesion exudates may be informative. Otherwise, skin biopsy may be warranted. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above and
         <a class="local">
          'Diagnosis and evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Empiric antimicrobial therapy of a lesion suspicious for ecthyma gangrenosum should include an agent with antipseudomonal activity (
         <a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">
          table 1
         </a>
         ). Once the causative organism and its susceptibility pattern are identified, directed therapy with a single active agent can be tailored to these results. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Burns
         </strong>
         –
         <em>
          P. aeruginosa
         </em>
         skin infection complicating burn injuries is associated with high mortality despite aggressive antibiotic therapy. Infected skin typically reveals discoloration of the burn eschar, bleeding in the subcutaneous tissue, and degeneration of the granulation tissue. Systemic signs and symptoms are usually present as well. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Physical findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The diagnosis of
         <em>
          P. aeruginosa
         </em>
         infection in burn patients is confirmed by quantitative cultures from a biopsy of the burned skin, as well as adjacent unburned tissue. A colony count of 10
         <sup>
          5
         </sup>
         organisms per gram of tissue is significant. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For empiric antimicrobial therapy of burn patients with known or suspected
         <em>
          P. aeruginosa
         </em>
         infections, we suggest a combination of two intravenous antipseudomonal agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We initiate therapy with
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         ,
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         , or an antipseudomonal carbapenem
         <strong>
          plus
         </strong>
         an aminoglycoside (
         <a class="graphic graphic_table graphicRef91115" href="/z/d/graphic/91115.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection following nail puncture
         </strong>
         –
         <em>
          P. aeruginosa
         </em>
         osteochondritis, osteomyelitis, and septic arthritis following nail puncture wound to the foot is a well-described complication. This syndrome occurs predominantly in children with a history of wearing tennis shoes. Evaluation, management, and prevention of pseudomonal puncture wound infections are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7661.html" rel="external">
          "Infectious complications of puncture wounds"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other syndromes
         </strong>
         – Other conditions for which empiric antipseudomonal therapy is indicated include toe web infection, green nail syndrome, and infectious perichondritis of the ear. Hot tub-associated folliculitis and "hot foot syndrome" due to
         <em>
          P. aeruginosa
         </em>
         typically resolve without antibiotic therapy. (See
         <a class="local">
          'Toe web infection'
         </a>
         above and
         <a class="local">
          'Green nail syndrome'
         </a>
         above and
         <a class="local">
          'Perichondritis of the ear'
         </a>
         above and
         <a class="local">
          'Hot tub-associated eruptions'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Roriz M, Maruani A, Le Bidre E, et al. Locoregional multiple nodular panniculitis induced by Pseudomonas aeruginosa without septicemia: three cases and focus on predisposing factors. JAMA Dermatol 2014; 150:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Unal S, Ersoz G, Demirkan F, et al. Analysis of skin-graft loss due to infection: infection-related graft loss. Ann Plast Surg 2005; 55:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sousa Dominguez A, Perez-Rodríguez MT, Nodar A, et al. Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam. J Antimicrob Chemother 2017; 72:1262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassan S, Kahn MD, Saraiya N, Nori P. Treatment of a complex orthopaedic infection due to extensively drug-resistant Pseudomonas aeruginosa. BMJ Case Rep 2018; 2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dietl B, Sánchez I, Arcenillas P, et al. Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes. Int J Antimicrob Agents 2018; 51:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sader HS, Castanheira M, Duncan LR, Mendes RE. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. Int J Infect Dis 2021; 113:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maraolo AE, Mazzitelli M, Trecarichi EM, et al. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications. Int J Antimicrob Agents 2020; 55:105891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shortridge D, Pfaller MA, Streit JM, Flamm RK. Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme. J Glob Antimicrob Resist 2020; 21:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buonomo AR, Maraolo AE, Scotto R, et al. Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience. Infection 2020; 48:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al Salman J, Al Dabal L, Bassetti M, et al. Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper. Int J Antimicrob Agents 2020; 56:106104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weng QY, Raff AB, Cohen JM, et al. Costs and Consequences Associated With Misdiagnosed Lower Extremity Cellulitis. JAMA Dermatol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zakhour J, Sharara SL, Hindy JR, et al. Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis. Antibiotics (Basel) 2022; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ribeiro M, Marinho P, Camilo C, Pinto S. Ecthyma gangrenosum as a clue to pseudomonas septicaemia. BMJ Case Rep 2022; 15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin SC, Chiang BL, Lee YJ, et al. Pseudomonas aeruginosa sepsis presenting as oral ecthyma gangrenosum in identical twins with Bruton tyrosine kinase gene mutation: Two case reports and review of the literature. J Microbiol Immunol Infect 2020; 53:1030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ismail IH, Adam J. Ecthyma gangrenosum as a presenting feature of X-linked agammaglobulinemia: A case study. Pediatr Neonatol 2022; 63:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarkar S, Patra AK, Mondal M. Ecthyma gangrenosum in the periorbital region in a previously healthy immunocompetent woman without bacteremia. Indian Dermatol Online J 2016; 7:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zomorrodi A, Wald ER. Ecthyma gangrenosum: considerations in a previously healthy child. Pediatr Infect Dis J 2002; 21:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bettens S, Delaere B, Glupczynski Y, et al. Ecthyma gangrenosum in a non-neutropaenic, elderly patient: case report and review of the literature. Acta Clin Belg 2008; 63:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Somer T, Finegold SM. Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis 1995; 20:1010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reich HL, Williams Fadeyi D, Naik NS, et al. Nonpseudomonal ecthyma gangrenosum. J Am Acad Dermatol 2004; 50:S114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fine JD, Miller JA, Harrist TJ, Haynes HA. Cutaneous lesions in disseminated candidiasis mimicking ecthyma gangrenosum. Am J Med 1981; 70:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beasley K, Panach K, Dominguez AR. Disseminated Candida tropicalis presenting with Ecthyma-Gangrenosum-like Lesions. Dermatol Online J 2016; 22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzaga Y, Jeunon T, Machado J, Nucci M. Ecthyma gangrenosum in neutropenic patients and the importance of an early skin biopsy for direct examination. An Bras Dermatol 2022; 97:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muggeo P, Zama D, Decembrino N, et al. Ecthyma Gangrenosum in Children With Cancer: Diagnosis at a Glance: A Retrospective Study From the Infection Working Group of Italian Pediatric Hematology Oncology Association. Pediatr Infect Dis J 2022; 41:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalil BA, Baillie CT, Kenny SE, et al. Surgical strategies in the management of ecthyma gangrenosum in paediatric oncology patients. Pediatr Surg Int 2008; 24:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russomanno K, Cardis M, Kirkorian AY. Ecthyma gangrenosum: The critical role of biofilms and other mechanisms of antibiotic resistance and implications for management. Pediatr Dermatol 2021; 38:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McManus AT, Mason AD Jr, McManus WF, Pruitt BA Jr. Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center. Eur J Clin Microbiol 1985; 4:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gang RK, Bang RL, Sanyal SC, et al. Pseudomonas aeruginosa septicaemia in burns. Burns 1999; 25:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Estahbanati HK, Kashani PP, Ghanaatpisheh F. Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics. Burns 2002; 28:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azzopardi EA, Azzopardi E, Camilleri L, et al. Gram negative wound infection in hospitalised adult burn patients--systematic review and metanalysis-. PLoS One 2014; 9:e95042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lachiewicz AM, Hauck CG, Weber DJ, et al. Bacterial Infections After Burn Injuries: Impact of Multidrug Resistance. Clin Infect Dis 2017; 65:2130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodgers GL, Mortensen J, Fisher MC, et al. Predictors of infectious complications after burn injuries in children. Pediatr Infect Dis J 2000; 19:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grisaru-Soen G, Lerner-Geva L, Keller N, et al. Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors. Pediatr Infect Dis J 2000; 19:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjerknes R, Vindenes H, Laerum OD. Altered neutrophil functions in patients with large burns. Blood Cells 1990; 16:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwacha MG, Ayala A, Chaudry IH. Insights into the role of gammadelta T lymphocytes in the immunopathogenic response to thermal injury. J Leukoc Biol 2000; 67:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peter FW, Schuschke DA, Barker JH, et al. The effect of severe burn injury on proinflammatory cytokines and leukocyte behavior: its modulation with granulocyte colony-stimulating factor. Burns 1999; 25:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pruitt BA Jr, Foley FD. The use of biopsies in burn patient care. Surgery 1973; 73:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gholami A, Majidpour A, Talebi-Taher M, et al. PCR-based assay for the rapid and precise distinction of Pseudomonas aeruginosa from other Pseudomonas species recovered from burns patients. J Prev Med Hyg 2016; 57:E81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weaver AJ, Brandenburg KS, Sanjar F, et al. Clinical Utility of PNA-FISH for Burn Wound Diagnostics: A Noninvasive, Culture-Independent Technique for Rapid Identification of Pathogenic Organisms in Burn Wounds. J Burn Care Res 2019; 40:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranjbar R, Owlia P, Saderi H, et al. Characterization of Pseudomonas aeruginosa strains isolated from burned patients hospitalized in a major burn center in Tehran, Iran. Acta Med Iran 2011; 49:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Almeida Silva KC, Calomino MA, Deutsch G, et al. Molecular characterization of multidrug-resistant (MDR) Pseudomonas aeruginosa isolated in a burn center. Burns 2017; 43:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fransén J, Huss FR, Nilsson LE, et al. Surveillance of antibiotic susceptibility in a Swedish Burn Center 1994-2012. Burns 2016; 42:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozkurt Z, Ertek M, Erol S, et al. The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns 2005; 31:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabbour JF, Sharara SL, Kanj SS. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections. Curr Opin Infect Dis 2020; 33:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibrahim D, Jabbour JF, Kanj SS. Current choices of antibiotic treatment for Pseudomonas aeruginosa infections. Curr Opin Infect Dis 2020; 33:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis 2019; 19:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orban C, Tomescu D. The importance of early diagnosis of sepsis in severe burned patients: outcomes of 100 patients. Chirurgia (Bucur) 2013; 108:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mansouri E, Blome-Eberwein S, Gabelsberger J, et al. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients. FEMS Immunol Med Microbiol 2003; 37:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tate D, Mawer S, Newton A. Outbreak of Pseudomonas aeruginosa folliculitis associated with a swimming pool inflatable. Epidemiol Infect 2003; 130:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Pseudomonas dermatitis/folliculitis associated with pools and hot tubs--Colorado and Maine, 1999-2000. MMWR Morb Mortal Wkly Rep 2000; 49:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacob JS, Tschen J. Hot Tub-Associated Pseudomonas Folliculitis: A Case Report and Review of Host Risk Factors. Cureus 2020; 12:e10623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregory DW, Schaffner W. Pseudomonas infections associated with hot tubs and other environments. Infect Dis Clin North Am 1987; 1:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverman AR, Nieland ML. Hot tub dermatitis: a familial outbreak of Pseudomonas folliculitis. J Am Acad Dermatol 1983; 8:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zichichi L, Asta G, Noto G. Pseudomonas aeruginosa folliculitis after shower/bath exposure. Int J Dermatol 2000; 39:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu Y, Cheng AS, Wang L, et al. Hot tub folliculitis or hot hand-foot syndrome caused by Pseudomonas aeruginosa. J Am Acad Dermatol 2007; 57:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosatsky T, Kleeman J. Superficial and systemic illness related to a hot tub. Am J Med 1985; 79:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiorillo L, Zucker M, Sawyer D, Lin AN. The pseudomonas hot-foot syndrome. N Engl J Med 2001; 345:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hot-foot syndrome. Clin Infect Dis 2012; 55:iii.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spernovasilis N, Psichogiou M, Poulakou G. Skin manifestations of Pseudomonas aeruginosa infections. Curr Opin Infect Dis 2021; 34:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobs RF, McCarthy RE, Elser JM. Pseudomonas osteochondritis complicating puncture wounds of the foot in children: a 10-year evaluation. J Infect Dis 1989; 160:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inaba AS, Zukin DD, Perro M. An update on the evaluation and management of plantar puncture wounds and Pseudomonas osteomyelitis. Pediatr Emerg Care 1992; 8:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher MC, Goldsmith JF, Gilligan PH. Sneakers as a source of Pseudomonas aeruginosa in children with osteomyelitis following puncture wounds. J Pediatr 1985; 106:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon M, Greenbaum H, Shemer A, et al. Toe Web Infection: Epidemiology and Risk Factors in a Large Cohort Study. Dermatology 2021; 237:902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weidner T, Tittelbach J, Illing T, Elsner P. Gram-negative bacterial toe web infection - a systematic review. J Eur Acad Dermatol Venereol 2018; 32:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aste N, Atzori L, Zucca M, et al. Gram-negative bacterial toe web infection: a survey of 123 cases from the district of Cagliari, Italy. J Am Acad Dermatol 2001; 45:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin JY, Shih YL, Ho HC. Foot bacterial intertrigo mimicking interdigital tinea pedis. Chang Gung Med J 2011; 34:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaitlin V, Zinn Z, Powers R. Macerated foot dermatitis related to occlusive footwear. W V Med J 2013; 109:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goiset A, Milpied B, Marti A, et al. Characteristics, Associated Diseases, and Management of Gram-negative Toe-web Infection: A French Experience. Acta Derm Venereol 2019; 99:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westmoreland TA, Ross EV, Yeager JK. Pseudomonas toe web infections. Cutis 1992; 49:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKay C, McBride P, Muir J. Plantar verrucous carcinoma masquerading as toe web intertrigo. Australas J Dermatol 2012; 53:e20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagliarello C, Paradisi M, Paradisi A. Letter: the most dangerous type of toe web 'infection'. Int Wound J 2012; 9:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldman, L, Fox, H. Greenish pigmentation of nail plats from Bacillus pyocyaneus infections: report of two cases. Arch Dermatol Syphilol 1944; 49:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agger WA, Mardan A. Pseudomonas aeruginosa infections of intact skin. Clin Infect Dis 1995; 20:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rallis E, Paparizos V, Flemetakis A, Katsambas A. Pseudomonas fingernail infection successfully treated with topical nadifloxacin in HIV-positive patients: report of two cases. AIDS 2010; 24:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hengge UR, Bardeli V. Images in clinical medicine. Green nails. N Engl J Med 2009; 360:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rigopoulos D, Rallis E, Gregoriou S, et al. Treatment of pseudomonas nail infections with 0.1% octenidine dihydrochloride solution. Dermatology 2009; 218:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samman PD. Management of disorders of the nails. Clin Exp Dermatol 1982; 7:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elewski BE. Bacterial infection in a patient with onychomycosis. J Am Acad Dermatol 1997; 37:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cumberworth VL, Hogarth TB. Hazards of ear-piercing procedures which traverse cartilage: a report of Pseudomonas perichondritis and review of other complications. Br J Clin Pract 1990; 44:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klug TE, Holm N, Greve T, Ovesen T. Perichondritis of the auricle: bacterial findings and clinical evaluation of different antibiotic regimens. Eur Arch Otorhinolaryngol 2019; 276:2199.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7643 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24671612" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Locoregional multiple nodular panniculitis induced by Pseudomonas aeruginosa without septicemia: three cases and focus on predisposing factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15985801" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Analysis of skin-graft loss due to infection: infection-related graft loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27999042" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29305368" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Treatment of a complex orthopaedic infection due to extensively drug-resistant Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29158144" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34670144" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31923569" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31648032" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Antimicrobial activity of ceftolozane/tazobactam tested against contemporary (2015-2017) Pseudomonas aeruginosa isolates from a global surveillance programme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31981091" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32721603" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27806170" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Costs and Consequences Associated With Misdiagnosed Lower Extremity Cellulitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36290092" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35318208" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Ecthyma gangrenosum as a clue to pseudomonas septicaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32340921" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pseudomonas aeruginosa sepsis presenting as oral ecthyma gangrenosum in identical twins with Bruton tyrosine kinase gene mutation: Two case reports and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35431148" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Ecthyma gangrenosum as a presenting feature of X-linked agammaglobulinemia: A case study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26955586" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Ecthyma gangrenosum in the periorbital region in a previously healthy immunocompetent woman without bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12488670" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Ecthyma gangrenosum: considerations in a previously healthy child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19170356" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Ecthyma gangrenosum in a non-neutropaenic, elderly patient: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7795045" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Vasculitides associated with infections, immunization, and antimicrobial drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15097944" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Nonpseudomonal ecthyma gangrenosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7234879" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cutaneous lesions in disseminated candidiasis mimicking ecthyma gangrenosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26990472" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Disseminated Candida tropicalis presenting with Ecthyma-Gangrenosum-like Lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35654651" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Ecthyma gangrenosum in neutropenic patients and the importance of an early skin biopsy for direct examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34694251" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ecthyma Gangrenosum in Children With Cancer: Diagnosis at a Glance: A Retrospective Study From the Infection Working Group of Italian Pediatric Hematology Oncology Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18427811" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Surgical strategies in the management of ecthyma gangrenosum in paediatric oncology patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33389781" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Ecthyma gangrenosum: The critical role of biofilms and other mechanisms of antibiotic resistance and implications for management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3924612" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10563687" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pseudomonas aeruginosa septicaemia in burns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12052372" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24751699" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Gram negative wound infection in hospitalised adult burn patients--systematic review and metanalysis-.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29194526" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Bacterial Infections After Burn Injuries: Impact of Multidrug Resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11055602" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Predictors of infectious complications after burn injuries in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11055596" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2190644" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Altered neutrophil functions in patients with large burns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10811004" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Insights into the role of gammadelta T lymphocytes in the immunopathogenic response to thermal injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10498354" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The effect of severe burn injury on proinflammatory cytokines and leukocyte behavior: its modulation with granulocyte colony-stimulating factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4703490" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The use of biopsies in burn patient care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27582633" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : PCR-based assay for the rapid and precise distinction of Pseudomonas aeruginosa from other Pseudomonas species recovered from burns patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30893424" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical Utility of PNA-FISH for Burn Wound Diagnostics: A Noninvasive, Culture-Independent Technique for Rapid Identification of Pathogenic Organisms in Burn Wounds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22071644" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Characterization of Pseudomonas aeruginosa strains isolated from burned patients hospitalized in a major burn center in Tehran, Iran.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27595453" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Molecular characterization of multidrug-resistant (MDR) Pseudomonas aeruginosa isolated in a burn center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27241732" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Surveillance of antibiotic susceptibility in a Swedish Burn Center 1994-2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15975720" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32022742" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Treatment of multidrug-resistant Gram-negative skin and soft tissue infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33148986" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Current choices of antibiotic treatment for Pseudomonas aeruginosa infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30292481" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23790789" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The importance of early diagnosis of sepsis in severe burned patients: outcomes of 100 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12832120" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12729186" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Outbreak of Pseudomonas aeruginosa folliculitis associated with a swimming pool inflatable.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11130858" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Pseudomonas dermatitis/folliculitis associated with pools and hot tubs--Colorado and Maine, 1999-2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33123436" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Hot Tub-Associated Pseudomonas Folliculitis: A Case Report and Review of Host Risk Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3504439" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Pseudomonas infections associated with hot tubs and other environments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6402527" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Hot tub dermatitis: a familial outbreak of Pseudomonas folliculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10809975" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Pseudomonas aeruginosa folliculitis after shower/bath exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17658195" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Hot tub folliculitis or hot hand-foot syndrome caused by Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3925779" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Superficial and systemic illness related to a hot tub.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11484690" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The pseudomonas hot-foot syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22730357" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Hot-foot syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33492004" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Skin manifestations of Pseudomonas aeruginosa infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2571647" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Pseudomonas osteochondritis complicating puncture wounds of the foot in children: a 10-year evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1603689" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : An update on the evaluation and management of plantar puncture wounds and Pseudomonas osteomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3920373" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Sneakers as a source of Pseudomonas aeruginosa in children with osteomyelitis following puncture wounds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33105147" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Toe Web Infection: Epidemiology and Risk Factors in a Large Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29055132" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Gram-negative bacterial toe web infection - a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11568743" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Gram-negative bacterial toe web infection: a survey of 123 cases from the district of Cagliari, Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21392473" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Foot bacterial intertrigo mimicking interdigital tinea pedis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24371857" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Macerated foot dermatitis related to occlusive footwear.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31502652" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Characteristics, Associated Diseases, and Management of Gram-negative Toe-web Infection: A French Experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1572222" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Pseudomonas toe web infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22571577" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Plantar verrucous carcinoma masquerading as toe web intertrigo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21985451" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Letter: the most dangerous type of toe web 'infection'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Greenish pigmentation of nail plats from Bacillus pyocyaneus infections: report of two cases
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7742434" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Pseudomonas aeruginosa infections of intact skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20386383" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Pseudomonas fingernail infection successfully treated with topical nadifloxacin in HIV-positive patients: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19279344" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Images in clinical medicine. Green nails.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18987463" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Treatment of pseudomonas nail infections with 0.1% octenidine dihydrochloride solution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7083625" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Management of disorders of the nails.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9308571" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Bacterial infection in a patient with onychomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2282313" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Hazards of ear-piercing procedures which traverse cartilage: a report of Pseudomonas perichondritis and review of other complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31079204" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Perichondritis of the auricle: bacterial findings and clinical evaluation of different antibiotic regimens.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
